The Latest & Greatest from ALK Positive, Inc
ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021.
Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of volunteer members from the ALK Positive Support Group, all ALK-positive patients, and/or caregivers.
The Board, Committees, and our CEO, are working together to improve the life expectancy and quality of life of ALK-positive cancer patients worldwide.
Here are a few of the latest highlights of what our nonprofit has been up to since the last update:
1) ALK Positive, Inc. participated at ASCO (American Society of Clinical Oncology) Annual Meeting in Chicago, IL, in June and hosted a “Key Opinion Leaders” Breakfast attended by multiple ALK experts and researchers as well as representatives from ALK Positive. Read our ASCO article in this newsletter to learn more about this exciting meeting. Special thanks to the Hedges Family and Tate Consulting for sponsoring the breakfast. Our representatives also attended a number of meetings with other doctors and industry representatives.
2) Registration for in-person attendance of our ALK Summit 2022 (July 30 & 31 in Denver, CO) is now closed, but registration for virtual attendance is still open until July 28. Be sure to register for access if you haven’t already done so. It is free! Here is the link to register and view the Summit agenda: https://www.alkpositive.org/alk-summit-2022
3) Our CEO, Dr. Scott Schell, has taken on the role of Director of Research and Clinical Affairs on an interim short-term basis in addition to his CEO duties. The purpose is to prepare the ground and finalize the hire of a permanent full-time Director of Research and Clinical Affairs which we hope to announce around September 2022.
4) Our Research Review Panel has been working tirelessly to complete the process of selection of our 2022 Research Grant Awards. As of the time of this writing, successful applicants from the first round of applications are going through the second round in which full research proposals have been submitted and are currently being reviewed and assessed by the Research Review Panel and our independent scientific advisors. It is expected that final decisions and award announcements will be made by fall 2022.